RCEL · AVITA Medical, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's liquidity position and the Company's current forecast of operating results and cash flows, management determined there is substantial doubt about the Company's ability to continue as a going concern over the next twelve months following the date of issuance of these Consolidated Financial Statements due to the Company's debt repayment obligations, recurring losses, and historical negative cash flows.”View the 10-Q filed Aug 6, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 30, 2020; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. AVITA Medical reported Q2 2026 record revenue of $21.7 million, up 18% year-over-year, raised full-year 2026 revenue guidance to $86-$89 million, and introduced new guidance to reach cash flow breakeven in Q4 2026.
- + Q2 revenue grew 18% year-over-year and 13% sequentially to a record $21.7 million
- + Introduced new guidance to reach cash flow breakeven and begin generating cash in Q4 2026
- + Gross margin expanded to 81.9%, up 70 basis points year-over-year
- + Operating expenses declined 6% year-over-year to $24.6 million while revenue grew
- + Net cash use improved to approximately $3.2 million from $9.9 million in Q1 2026
- + Net loss improved to $7.7 million from $9.9 million in the prior-year period
- − Cohealyx and PermeaDerm carry lower ASPs (50% and 60% respectively), pressuring overall gross margin percentage as they grow
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RCEL
this stock
AVITA Medical, Inc.
|
$305.56M | +195.4% | +11.5% | — | 9.5% |
|
ABT
Abbott Laboratories
|
$177.58B | -17.7% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -2.4% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -19.8% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$64.91B | -52.8% | +12.5% | 18.1 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 30, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RCEL | -9.0% | +29.8% | +158.0% | +0.9% | +195.4% |
| SPY | -1.2% | -2.0% | +16.1% | -0.8% | +11.6% |
| vs SPY | -7.8% | +31.8% | +141.9% | +1.7% | +183.8% |